Technology and Heart Failure Therapeutics® (THT®) is sponsored by the Cardiovascular Research Foundation® (CRF®) and partially funded through educational opportunities from commercial supporters. This program is made possible in part by our industry partners who, like CRF®, are dedicated to educating medical professionals and the public to enhance patient outcomes. CRF® gratefully acknowledges support from the following:
Educational Grant Support
Technology and Heart Failure Therapeutics® (THT®) is sponsored by the Cardiovascular Research Foundation® (CRF®) and is made possible, in part, through independent educational grants from commercial supporters whose shared commitment to advancing medical education helps improve patient outcomes.
We gratefully acknowledge our Benefactors for their generous support.
Major Benefactors
- Alnylam Pharmaceuticals
- Edwards Lifesciences
- Johnson & Johnson MedTech | Heart Recovery
Benefactors
- Procyrion, Inc.
- Vectorious Medical Technologies
- WhiteSwell
Industry Sponsors and Partners
We would like to thank our sponsors for their generous support of Technology and Heart Failure Therapeutics® (THT®) through financial and in-kind contributions, including support for academic satellite programs, hands-on training, exhibits, and other industry-led activities.
All sponsorship is provided without influence over the planning, content, or execution of all CRF® educational activities. CRF® maintains full independence over its educational programming to ensure it remains free from commercial bias.
We gratefully acknowledge the following sponsors:
- Abbott
- Alleviant Medical
- Alnylam Pharmaceuticals
- Analog Devices
- Ancora Heart
- AstraZeneca
- Boston Scientific
- BrioHealth Solutions
- Cambrian Health
- Corvia
- CVRx
- Edwards Lifesciences
- Emyosound
- Fire1
- Getinge
- ImpediMed
- Impulse Dynamics
- Johnson & Johnson MedTech | Heart Recovery
- MannKind
- SynCardia
- Teleflex
- Tenax Therapeutics
- Ultromics